Halozyme Therapeutics Inc.
10/06/2025 | Press release | Distributed by Public on 10/06/2025 14:58
Management Change/Compensation (Form 8-K)
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(c) On October 1, 2025, Cortney Caudill was appointed as Senior Vice President, Chief Operating Officer of Halozyme Therapeutics, Inc. (the "Company"), effective immediately. Ms. Caudill (age 49) has served as the Company's Senior Vice President, Chief Operations Officer since October 2023. Prior to joining the Company, from 2019 to October 2023, Ms. Caudill served in roles with increasing responsibility at Aeglea Biotherapeutics, Inc., a biotechnology company, including Vice President of Manufacturing, Senior Vice President, Technical Operations and most recently as Chief Product Officer. From 2002 to 2018, she held operational roles of increasing responsibility at various life sciences companies such as Cambrex Bioscience, Vaxagen, Inc., Genentech, Vetter Pharma International, Samsung Biologics, Baxalta and Eaulife NA. She received her B.S. degree in biology and her B.A degree in psychology from the University of Texas.
There are no family relationships between Ms. Caudill and any director, executive officer or person nominated or chosen by the Company to become a director or executive officer. Ms. Caudill does not have a direct or indirect material interest in any transaction or arrangement in which the Company is a participant.
Ms. Caudill's initial annual base salary as Chief Operating Officer will be $600,000 and she will be eligible to participate in the Company's executive officer incentive plans, with a 2025 bonus target equal to 50% of her base salary. Ms. Caudill will be eligible to receive long-term incentive awards in accordance with the Compensation Committee's equity award grant practices for the Company's executive officers. In connection with her appointment as Chief Operating Officer, Ms. Caudill will receive an equity award valued at $500,000 delivered 50% in stock options and 50% in restricted stock units. The options and restricted stock units will vest in accordance with the Company's standard four-year vesting schedule.
Halozyme Therapeutics Inc. published this content on October 06, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on October 06, 2025 at 20:58 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]